Acorda Therapeutics CEO Dr. Ron Cohen discusses the phase 2 studies happening on its mobility improvement drug Ampyra, and what's next for the company.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT